GLI 5021
Latest Information Update: 05 Dec 2006
Price :
$50 *
At a glance
- Originator Galileo Pharmaceuticals
- Class Anti-ischaemics; Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 07 May 2003 Galileo Laboratories is now called Galileo Pharmaceuticals
- 14 Jun 2002 Preclinical trials in Stroke in USA (unspecified route)